News | March 03, 2023
ProBioGen’s growth strategy continues successfully
Julian Collins, Jana Windt and Michiel Stork join biopharma company’s leadership team
Julian Collins, Jana Windt and Michiel Stork join biopharma company’s leadership team
Receives regulatory approval for its molecule ‘Selumetinib’ in India
The company expects the GMP approval from Saudi Food and Drug Authority (SFDA) to soon pave the way for marketing authorizations from the largest market in the GCC region
New workflow integrates the xCELLigence RTCA HT with the BioTek BioSpa 8 Automated Incubator
Merck and Ridgeback will appeal the decision and request a re-examination of the CHMP’s opinion.
Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial
This action follows the recent acceptance of the Marketing Authorization Application (MAA) for Pfizer’s RSV vaccine candidate by the European Medicines Agency
The safety profile of LAGEVRIO in this trial was generally consistent with that observed in previously reported clinical studies
At commercial scale, Bluestem's patent pending technologies will reduce carbon emission by an estimated 75% or more and be cost-competitive with petroleum based chemicals
Subscribe To Our Newsletter & Stay Updated
